Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Everolimus

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    40-O-(2-hydroxyethyl)-rapamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sapu Nano Doses First Patient in Sapu003 Phase 1b Trial
    Sapu Nano Doses First Patient in Sapu003 Phase 1b Trial

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293951/0/en/sapu-nano-announces-first-patient-dosed-in-phase-1b-trial-of-sapu003-an-intravenous-deciparticle-formulation-of-everolimus.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Sapu Nano To Unveil Everolimus Toxicology Data At SOT 2026
    Sapu Nano To Unveil Everolimus Toxicology Data At SOT 2026

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260310/0/en/Sapu-Nano-to-Present-Everolimus-Toxicology-Data-at-SOT-2026-Annual-Meeting.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    ITM Announces COMPETE Analyses for ITM-11 in pNETs at ENETS 2026
    ITM Announces COMPETE Analyses for ITM-11 in pNETs at ENETS 2026

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3249959/0/en/ITM-Announces-Phase-3-COMPETE-Trial-Post-Hoc-Subgroup-Analyses-with-n-c-a-Lu-edotreotide-ITM-11-in-Patients-with-Pancreatic-Neuroendocrine-Tumors-at-ENETS-2026-Conference.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Eugia Pharma Receives USFDA Approval For Everolimus Tablets
    Eugia Pharma Receives USFDA Approval For Everolimus Tablets

    26 Feb 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/eugia-pharma-receives-usfda-approval-for-everolimus-tablets-19224

    INDPHARMAPOST
    26 Feb 2026
    Share Share
    Eugia Pharma’s Generics Everolimus Receives Approval in US
    Eugia Pharma’s Generics Everolimus Receives Approval in US

    25 Feb 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219533

    FDA
    25 Feb 2026
    Share Share
    FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated
    FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/20/3241682/0/en/FDA-accepts-New-Drug-Application-for-Roche-s-giredestrant-in-ESR1-mutated-ER-positive-advanced-breast-cancer.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.